|Sample selection and attrition|
|Patients with continuous enrollment (index date minus 365 to index date)||72,978||48.3|
|Patients with index cancer (BC, CRC, LC, NHL, Ovarian)||18,186||24.9|
|Patients meeting criteria for eligible course||10,219||56.2|
|Patients without stem cell transplant||10,207||99.9|
|Patients without use of nursing facility||9,989||97.9|
|Patients with G-CSF use during at least one cycle||4,684||46.9|
|Patients without radiation on index date||4,531||96.7|
|Patients without more than one primary cancer site†||3,958||87.4|
|Patients with prophylactic G-CSF use in at least one cycle||3,535||89.3|
|Patients with prophylactic pegfilgrastim use||3,372||95.4|
|Patients with prophylactic filgrastim use||163||4.6|
|Patient-cycles with G-CSF prophylaxis in 3,535 patients||12,056|
|Patient-cycles with G-CSF prophylaxis [included up to the 9th cycle]||11,968|
BC – breast cancer, CRC – colorectal cancer, LC – lung cancer, and NHL – non-Hodgkin’s lymphoma.
* Patients with any evidence of chemotherapy from January 1, 2005 to February 28, 2009 (index date set to first administration) and no chemotherapy from index date −365 to index date −1.
† Primary cancers defined as: 140.xx – 172.xx, 174.xx – 195.xx and 199.xx – 208.xx.
Naeim et al.
Naeim et al. BMC Cancer 2013 13:11 doi:10.1186/1471-2407-13-11